Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30546567 | 0.86 | GSK3B (0.75) | GSK3BNPC1CA12CA9RAB9A | |
| SCHEMBL543706 | 0.86 | GSK3B (0.75) | GSK3BNPC1CA12CA9RAB9A | |
| SCHEMBL1906596 | 0.85 | GSK3B (0.73) | GSK3BNPC1CA12CA9RAB9A | |
| Methane SCHEMBL11813940 | 0.84 | GSK3B (0.73) | GSK3BNPC1CA12CA9RAB9A | |
| SCHEMBL7345361 | 0.84 | SMN1; SMN2 (0.63) | GSK3BNPC1CA12CA9CA1 | |
| SCHEMBL694554 | 0.83 | GSK3B (0.71) | GSK3BNPC1CA12CA9RAB9A | |
| SCHEMBL14711680 | 0.83 | GSK3B (1.00) | GSK3BNPC1CA12CA9RAB9A | |
| SCHEMBL29236638 | 0.81 | GSK3B (0.68) | GSK3BNPC1CA12CA9RAB9A | |
| SCHEMBL24099161 | 0.80 | ALDH1A1 (0.64) | NPC1RAB9AKDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL1609155 | 0.80 | NPC1 (1.00) | GSK3BNPC1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184477-A | Method for preparing chiral amino alcohol compound by catalyzing amino ketone with nickel metal by using water as hydrogen source | 云南民族大学 | 2024-06-14 | — | — | CN | disclosed |
| EP-2421864-B1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| US-8461175-B2 | 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| EP-2421864-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122272-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-28 | — | — | WO | disclosed |
| EP-1075475-B1 | HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE PRODUCTION | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-20020132809-A1 | Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1075475-A1 | HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE PRODUCTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999057114-A1 | HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE PRODUCTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132809-A1 | Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production | NOS1, NOS3, NOS2 | GSK3B 1016/4885NPC1 1265/4885CA12 3077/4885 |
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, CYP4F3, HCCS | GSK3B 2594/4885NPC1 326/4885CA12 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.